Rexahn, University Partner for Drug Development
Complete the form below to unlock access to ALL audio articles.
Scientists at a University of Maryland, Baltimore research center are teaming with a Rockville bioscience company to develop drugs using nanotechnology.
Rexahn Pharmaceuticals is looking to an emerging field known as "nanomedicine" to make stronger cancer-fighting drugs and central nervous system therapies.
Rexahn CEO Chang Ahn said in a statement a partnership with the University of Maryland's Center for Nanomedicine and Cellular Delivery in Baltimore, "will help expand our candidate pipeline and allow us to provide more targeted, efficient and potent therapies for patients. Both are key components of our business strategy."
Post-doctoral fellows at the university will be picked to work at Rexahn. Researchers hope nanomedicine can lead to advances in "targeted delivery" - using technology to target, for example, cancer cells that can be vanquished without damaging surrounding healthy cells.
